Inventiva SA reported cash and cash equivalents of €97.6 million and €24.7 million in short-term deposits as of September 30, 2025. Revenues for the first nine months of 2025 reached €4.5 million, compared to none in the same period of 2024. The company's revenues included a $10 million milestone payment and $5 million in credit notes from Chia Tai Tianqing Pharmaceutical Group under a license agreement. Net cash used in investing activities for the period was (€25.0) million, a change mainly due to variations in short-term deposits. Inventiva expects its cash position to fund operations until the end of the first quarter of 2027, or until mid-third quarter 2027 if additional financing is secured. Topline results from the NATiV3 study are expected in the second half of 2026.